drug · protein

YORVIPATH

updated 3mo ago

by $ASND Ascendis Pharma A/S🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 4

Protein drug with a maximum clinical stage of Approval, with an approval for hypoparathyroidism.

targets

Parathyroid hormone/parathyroid hormone-related peptide receptor

all catalysts(0)

nothing on the calendar yet

Trials studying YORVIPATH

phase3A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidismrecruitingn=12
phase3A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidismrecruitingn=36
—A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)recruitingn=10
—A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeedingrecruitingn=50
—Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidismapproved for marketing

News(0)

no news has mentioned this drug yet

brand

YORVIPATH

trade names

Yorvipath

generic

PALOPEGTERIPARATIDE

MOA

12.1 Mechanism of Action At physiological conditions, palopegteriparatide releases PTH(1-34) to maintain a continuous systemic exposure. Endogenous PTH maintains extracellular calcium and phosphate homeostasis by increasing serum calcium and decreasing serum phosphate. These effects are mediated by stimulating bone turnover to mobilize calcium and phosphate from bone, promoting renal calcium reabsorption and phosphate excretion, and facilitating active vitamin D synthesis, in turn increasing intestinal absorption of calcium and phosphate. Similar to endogenous PTH, PTH(1-34) released from palopegteriparatide exerts these effects through its main receptor, parathyroid hormone 1 receptor (PTH1R), which is highly expressed on osteoblasts, osteocytes, renal tubular cells, and in several other tissues.

indication

1 INDICATIONS AND USAGE YORVIPATH is indicated for the treatment of hypoparathyroidism in adults. YORVIPATH is a parathyroid hormone analog (PTH(1-34)) indicated for the treatment of hypoparathyroidism in adults. ( 1 ) Limitations of Use : Not studied for acute post-surgical hypoparathyroidism. ( 1 ) Titration scheme only evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D treatment. ( 1 ) Limitations of Use YORVIPATH was not studied for acute post-surgical hypoparathyroidism. YORVIPATH's titration scheme was only evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D treatment [see Dosage and Administration (2.3 , 2.4) and Clinical Studies (14) ] .

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 15m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · protein

save

YORVIPATH

updated 3mo ago

by $ASND Ascendis Pharma A/S🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 4

Protein drug with a maximum clinical stage of Approval, with an approval for hypoparathyroidism.

targets

Parathyroid hormone/parathyroid hormone-related peptide receptor

all catalysts(0)

nothing on the calendar yet

Trials studying YORVIPATH

News(0)

no news has mentioned this drug yet

brand

YORVIPATH

trade names

Yorvipath

generic

PALOPEGTERIPARATIDE

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 15m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

YORVIPATH

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying YORVIPATH

News(0)

Report a data issue

comments(0)

YORVIPATH

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying YORVIPATH

News(0)

Report a data issue

comments(0)